Safety Profile of HTX-019 Administered as an Intravenous Push in Cancer Patients: A Retrospective Review

Introduction HTX-019 [CINVANTI ® (aprepitant injectable emulsion)] is a neurokinin 1 receptor antagonist (NK-1 RA) approved as a 30-min infusion for preventing acute and delayed chemotherapy-induced nausea and vomiting. HTX-019 has been generally well tolerated when administered as a 30-min infusion...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Advances in therapy 2019-03, Vol.36 (3), p.662-669
1. Verfasser:	Walton, Gary D.
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Intravenous Adolescent Adult Aged Aged, 80 and over Antiemetics - administration & dosage Antineoplastic Agents - adverse effects Aprepitant - administration & dosage Cardiology Endocrinology Female Humans Internal Medicine Male Medicine Medicine & Public Health Middle Aged Morpholines - administration & dosage Nausea - chemically induced Nausea - prevention & control Neoplasms - drug therapy Neurokinin-1 Receptor Antagonists - administration & dosage Oncology Original Research Pharmacology/Toxicology Retrospective Studies Rheumatology Vomiting - chemically induced Vomiting - prevention & control Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!